Guardant Health, Inc.

Equities

GH

US40131M1099

Real-time Estimate Cboe BZX Other stock markets 11:59:16 18/05/2026 pm IST			5-day change	1st Jan Change
94.66 ^USD	-0.28%		-2.03%	-7.24%

14/05	Guardant Health Insider Sold Shares Worth $5,016,000, According to a Recent SEC Filing	MT
13/05	Guardant Health, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:40 AM

Transcript : Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01

Published on 03/11/2026 at 11:50 pm IST - Modified on 03/12/2026 at 12:51 am IST

S&P Capital IQ

Presenter Speech
Luke Sergott (Analysts)

Good afternoon, everybody. I'm Luke Sergott, I cover life science tools and diagnostics here at Barclays. With me, I have AmirAli Talasaz, co-CEO; and Mike

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Guardant Health, Inc.

14/05	Guardant Health Insider Sold Shares Worth $5,016,000, According to a Recent SEC Filing	MT
13/05	Guardant Health, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:40 AM
08/05	Guardant Health, Inc., Q1 2026 Earnings Call, May 07, 2026
08/05	Guardant Health Q1 Adjusted Loss Narrows, Revenue Rises; Raises Full-Year Revenue Guidance	MT
08/05	Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.30B - $1.32B, vs. FactSet Est of $1.27B	MT
08/05	Earnings Flash (GH) Guardant Health, Inc. Posts Q1 Adjusted Loss $0.45 per Share, vs. FactSet Est of $-0.45	MT
08/05	Earnings Flash (GH) Guardant Health, Inc. Reports Q1 Revenue $301.7M, vs. FactSet Est of $279.2M	MT
08/05	Guardant Health, Inc. Raises Earnings Guidance for the Full Year 2026	CI
04/05	Guardant Health Says FDA Approved Liquid Biopsy Test for Certain Breast Cancer Diagnostics	MT
04/05	Guardant Health receives FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer's Veppanu (vepdegestrant) for patients with ER+/Her2- advanced breast cancer with ESR1 mutations	RE
04/05	Guardant Health Announces FDA Approval for Guardant360 Cdx as Companion Diagnostic for Arvinas and Pfizer?S Veppanu for Er+/Her2- Advanced Breast Cancer with Esr1 Mutations	CI
30/04	Guardant Health and Nuvalent Enter Multi-Year Strategic Collaboration for Oncology Drug Development	CI
28/04	Guardant Health Says Chief Medical Officer to Resign	MT
28/04	Guardant Health, Inc. Announces Resignation of Craig Eagle, M.D. as Chief Medical Officer, Effective May 8, 2026	CI